COAG Hemab Therapeutics Holdings, In
$38.40▲ +6.61%
Healthcare
Other
After hours
$38.40▲ +0.00%
Oct 27, 4:17 PM ET
Volume 380.0K
Avg Volume (10D) 344.7K
Key Metrics & Fundamentals
Market Cap
$1.79B
P/E Ratio
–
Div Yield
0.00%
52W Range
23.00 - 55.42
% vs 50 MA
-0.37%
% vs 200 MA
–%
RSI-14
60.8
MACD Histogram
+1.2200
Beta (1Y vs SPY)
1.30
Free Cash Flow
-$22.66M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$26.00M
COGS
–
Operating Exp
$26.08M
Operating Income
-$26.08M
EBIT
-$26.08M
Pretax Income
-$24.05M
Net Income
-$24.15M
EPS (Diluted)
-0.80
Price & Volume History
Loading chart…
Recent News
JPMorgan Initiates Hemab Therapeutics at Overweight With $70 Price Target
MT Newswires · Oct 15, 2026 7:41 AM ET
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
Simply Wall St. · Sep 28, 2026 9:07 PM ET
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
GlobeNewswire · Sep 24, 2026 4:01 PM ET
Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study
MT Newswires · Sep 17, 2026 8:43 AM ET
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
GlobeNewswire · Sep 17, 2026 8:00 AM ET
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating
MT Newswires · Aug 11, 2026 11:48 AM ET
Hemab Therapeutics' Q2 Net Loss Narrows
MT Newswires · Aug 11, 2026 7:33 AM ET
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 11, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See COAG's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.